Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206J. Clin. Oncol 2020 Nov 02;[EPub Ahead of Print], H Kenmotsu, S Niho, M Tsuboi, M Wakabayashi, G Ishii, K Nakagawa, H Daga, H Tanaka, H Saito, K Aokage, T Takahashi, T Menju, T Kasai, I Yoshino, K Minato, M Okada, J Eba, H Asamura, Y Ohe, SI Watanabe
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.